Chokhani Ramesh, Muttalif Abdul Razak, Gunasekera Kirthi, Mukhopadhyay Aniruddha, Gaur Vaibhav, Gogtay Jaideep
Norvic International Hospital, Kathmandu, Nepal.
MAHSA University, Selangor, Malaysia.
Pulm Ther. 2021 Jun;7(1):251-265. doi: 10.1007/s41030-021-00153-w. Epub 2021 Apr 15.
There is much recent data from Nepal, Sri Lanka and Malaysia that can help us understand the practice patterns of physicians regarding the diagnosis and management of chronic obstructive pulmonary disease (COPD) in these countries. We conducted this survey to understand the practice patterns of physicians related to the diagnosis and management of COPD in these three countries.
This questionnaire-based, observational, multicentre, cross-sectional survey was carried out with 438 randomly selected physicians consulting COPD patients.
In the survey, 73.29% of the physicians consulted at least five COPD patients daily (all patients > 40 years of age). 31.14% of the COPD patients visiting their doctors were women. Among physicians, 95.12% reported that at least 70% of their patients were smokers. 34.18% of the physicians did not routinely use spirometry to diagnose COPD. Most physicians preferred a short-acting β-agonist (SABA) (28.19%) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Group-A and long-acting muscarinic receptor antagonist plus long-acting β-agonist/inhaled corticosteroids (LAMA + LABA/ICS) in both the GOLD Group-C (39.86%) and Group-D (72.89%) patients. A significant number (40.67%) of physicians preferred LABA/LAMA for their GOLD Group-B patients. A pressurised metered dose inhaler (pMDI) with or without spacer was the most preferred device. Only 23.67% of the physicians believed that at least 70% of their patients had good adherence (> 80%) to therapy. Up to 54.42% of the physicians prescribed inhalation therapy to every COPD patient. Also, 39.95% of the physicians evaluated their patients' inhalation technique on every visit. Up to 52.67% of the physicians advised home nebulisation to > 10% of patients, with nebulised SABA/short-acting muscarinic receptor antagonist (SAMA) being the most preferred management choice. Most physicians offered smoking cessation advice (94.16%) and/or vaccinations (74.30%) as non-pharmacological management, whereas pulmonary rehabilitation was offered by a smaller number of physicians. Cost of therapy and poor technique were the most common reasons for non-adherence to COPD management therapy.
Awareness of spirometry can be increased to improve the diagnosis of COPD. Though physicians are following the GOLD strategy recommendations for the pharmacological and non-pharmacological management of COPD, awareness of spirometry could be increased to improve proper diagnosis. Regular device demonstration during each visit can improve the inhalation technique and can possibly increase adherence to treatment.
最近来自尼泊尔、斯里兰卡和马来西亚的大量数据有助于我们了解这些国家医生对慢性阻塞性肺疾病(COPD)的诊断和管理的实践模式。我们开展这项调查以了解这三个国家医生对COPD的诊断和管理的实践模式。
这项基于问卷的观察性多中心横断面调查针对438名随机选择的诊治COPD患者的医生进行。
在调查中,73.29%的医生每天至少诊治5名COPD患者(所有患者年龄>40岁)。就诊的COPD患者中31.14%为女性。在医生中,95.12%报告称其至少70%的患者为吸烟者。34.18%的医生在诊断COPD时不常规使用肺功能仪。大多数医生在慢性阻塞性肺疾病全球倡议(GOLD)A组中更倾向于使用短效β受体激动剂(SABA)(28.19%),而在GOLD C组(39.86%)和D组(72.89%)患者中更倾向于使用长效毒蕈碱受体拮抗剂加长效β受体激动剂/吸入性糖皮质激素(LAMA+LABA/ICS)。相当一部分(40.67%)医生在GOLD B组患者中更倾向于使用LABA/LAMA。有或无储雾罐的压力定量吸入器(pMDI)是最常用的装置。只有23.67%的医生认为其至少70%的患者对治疗的依从性良好(>80%)。高达54.42%的医生对每位COPD患者都开具吸入疗法。此外,39.95%的医生每次就诊时都会评估患者的吸入技术。高达52.67%的医生建议超过10%的患者进行家庭雾化治疗,雾化SABA/短效毒蕈碱受体拮抗剂(SAMA)是最常用的治疗选择。大多数医生提供戒烟建议(94.16%)和/或疫苗接种(74.30%)作为非药物治疗,而提供肺康复治疗的医生较少。治疗费用和技术不佳是COPD管理治疗不依从的最常见原因。
可以提高对肺功能仪的认识以改善COPD的诊断。尽管医生在遵循GOLD策略对COPD进行药物和非药物管理的建议,但可以提高对肺功能仪的认识以改善正确诊断。每次就诊时定期进行装置演示可以改善吸入技术,并可能提高治疗依从性。